T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Tumour infiltrating lymphocytes (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 31 Dec 2018 Status changed from active, no longer recruiting to completed.
- 10 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.
- 28 Jun 2018 Status changed from recruiting to active, no longer recruiting.